{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Replimune Group, Inc."},"Symbol":{"label":"Symbol","value":"REPL"},"Address":{"label":"Address","value":"500 UNICORN PARK,3RD FLOOR, WOBURN, Massachusetts, 01801, United States"},"Phone":{"label":"Phone","value":"+1 781 222-9600"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3."},"CompanyUrl":{"label":"Company Url","value":"https://www.replimune.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Konstantinos Xynos","title":"Chief Medical Officer"},{"name":"Sushil Patel","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}